Abiopharma

IO Biotech, Inc. - IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Vir Biotechnology - Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots